IDEAYA Biosciences, Inc. Cash and Restricted Cash
IDEAYA Biosciences, Inc. (IDYA) had Cash and Restricted Cash of $273.87 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $273.87M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $158.80M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $113.84M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $299.73M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $273.87M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $158.80M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $113.84M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $299.73M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $115.45M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $130.80M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $85.18M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $401.19M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $183.96M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $109.10M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $157.78M 10-K · filed 2026-02-17 |
| 2023-09-30 | $152.57M 10-Q · filed 2024-11-04 |
| 2023-06-30 | $103.56M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $67.34M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $68.74M 10-K · filed 2026-02-17 |
| 2022-09-30 | $102.06M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $49.21M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $55.40M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $92.15M 10-K · filed 2025-02-18 |
| 2021-09-30 | $108.53M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $90.53M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $136.86M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $72.14M 10-K · filed 2024-02-20 |
| 2020-09-30 | $81.34M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $147.65M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $35.57M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $34.17M 10-K · filed 2023-03-07 |
| 2019-09-30 | $38.95M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $88.22M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $35.41M 10-Q · filed 2020-05-12 |
| 2018-12-31 | $20.61M 10-K · filed 2022-03-18 |
| 2018-09-30 | $21.59M 10-Q · filed 2019-11-13 |
| 2018-06-30 | $24.98M 10-Q · filed 2019-08-12 |
| 2017-12-31 | $6.03M 10-K · filed 2021-03-23 |
| 2016-12-31 | $9.69M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |